sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Środki przeciwnowotworowe - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib pharmascience 37,5 mg kapsułki twarde
pharmascience international limited - sunitynibu chlorowodorek - kapsułki twarde - 37,5 mg
sunitinib pharmascience 12,5 mg kapsułki twarde
pharmascience international limited - sunitynibu chlorowodorek - kapsułki twarde - 12,5 mg
sunitinib pharmascience 25 mg kapsułki twarde
pharmascience international limited - sunitynibu chlorowodorek - kapsułki twarde - 25 mg
sunitinib pharmascience 50 mg kapsułki twarde
pharmascience international limited - sunitynibu chlorowodorek - kapsułki twarde - 50 mg
sunitinib stada 12,5 mg kapsułki twarde
stada arzneimittel ag - sunitinibum - kapsułki twarde - 12,5 mg
sunitinib stada 25 mg kapsułki twarde
stada arzneimittel ag - sunitinibum - kapsułki twarde - 25 mg
sunitinib stada 37,5 mg kapsułki twarde
stada arzneimittel ag - sunitinibum - kapsułki twarde - 37,5 mg
sunitinib stada 50 mg kapsułki twarde
stada arzneimittel ag - sunitinibum - kapsułki twarde - 50 mg
sunitinib synthon 25 mg kapsułki twarde
synthon b.v. - sunitynibu jabłaczan - kapsułki twarde - 25 mg